AdAlta Updates

Adalta_Concept01.01

  • Drug Discovery Company AdAlta Raises AU$10m in Over-Subscribed Australian IPO to Accelerate New Therapies for Lung Fibrosis
  • AdAlta raises AU$10 million in over-subscribed IPO on the ASX (ASX: 1AD)
  • Proceeds from fund raising to support Phase 1 development of its lead candidate drug (AD-114) to treat lung fibrosis, for onward partnering to big pharma
  • Powerful proprietary technology platform, that generates new biological drugs called i-bodies to be marketed to global biotech and pharmaceutical companies

Full Story: adalta.com.au